Lf modification was designed to enhance BBB permeability and glioma targeting by binding to Lf receptors (LfR) and LDL receptor-related protein (LRP), which are overexpressed in both BBB endothelial cells and glioma cells. The gene discussed is LRP1; the disease is central nervous system cancer.